A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
39actual
Sites
8
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-21 | actual | When the study began enrolling |
| Primary completion | 2024-07-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic NSCLC
Interventions
- Drug: Ceralasertib
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFObjective response rate (ORR)
measured At month 6 after the last patient's first dose (approximately 18 months).
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed